Characterization of gut microbiota profiles by disease activity in patients with Crohn's disease using data mining analysis of terminal restriction fragment length polymorphisms

Andoh,Akira; Kobayashi,Toshio; Kuzuoka,Hiroyuki; Tsujikawa,Tomoyuki; Suzuki,Yasuo; Hirai,Fumihito; Matsui,Toshiyuki; Nakamura,Shiro; Matsumoto,Takayuki; Fujiyama,Yoshihide

doi:10.3892/br.2014.252

Characterization of gut microbiota profiles by disease activity in patients with Crohn's disease using data mining analysis of terminal restriction fragment length polymorphisms

Authors:
- Akira Andoh
- Toshio Kobayashi
- Hiroyuki Kuzuoka
- Tomoyuki Tsujikawa
- Yasuo Suzuki
- Fumihito Hirai
- Toshiyuki Matsui
- Shiro Nakamura
- Takayuki Matsumoto
- Yoshihide Fujiyama
View Affiliations

Affiliations: Division of Mucosal Immunology, Graduate School of Medicine, Shiga University of Medical Science, Otsu, Shiga 520‑2192, Japan, Miyagi University, Sendai, Miyagi 982‑0215, Japan, Research and Development Laboratories, EN Otsuka Pharmaceutical Co., Ltd., Hanamaki, Iwate 025‑0312, Japan, Department of Medicine, Shiga University of Medical Science, Otsu, Shiga 520‑2192, Japan, Department of Internal Medicine, Sakura Medical Center, Toho University, Sakura, Chiba 285‑8741, Department of Gastroenterology, Chikushi Hospital, Fukuoka University, Chikushino, Fukuoka 814‑0180, Japan, Division of Lower Gastroenterology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Hyogo 663‑8131, Japan
Published online on: March 14, 2014 https://doi.org/10.3892/br.2014.252
Pages: 370-373

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The gut microbiota plays a significant role in the pathogenesis of Crohn's disease (CD). In this study, we analyzed the disease activity and associated fecal microbiota profiles in 160 CD patients and 121 healthy individuals. Fecal samples from the CD patients were collected during three different clinical phases, the active (n=66), remission‑achieved (n=51) and remission‑maintained (n=43) phases. Terminal restriction fragment length polymorphism (T‑RFLP) and data mining analysis using the Classification and Regression Tree (C&RT) approach were performed. Data mining provided a decision tree that clearly identified the various subject groups (nodes). The majority of the healthy individuals were divided into Node‑5 and Node‑8. Healthy subjects comprised 99% of Node‑5 (91 of 92) and 84% of Node‑8 (21 of 25 subjects). Node‑3 was characterized by CD (136 of 160 CD subjects) and was divided into Node‑6 and Node‑7. Node‑6 (n=103) was characterized by subjects in the active phase (n=48; 46%) and remission‑achieved phase (n=39; 38%) and Node‑7 was characterized by the remission‑maintained phase (21 of 37 subjects; 57%). Finally, Node‑6 was divided into Node‑9 and Node‑10. Node‑9 (n=78) was characterized by subjects in the active phase (n=43; 55%) and Node‑10 (n=25) was characterized by subjects in the remission‑maintained phase (n=16; 64%). Differences in the gut microbiota associated with disease activity of CD patients were identified. Thus, data mining analysis appears to be an ideal tool for the characterization of the gut microbiota in inflammatory bowel disease.

View Figures

View References

1	Mayer L: Evolving paradigms in the pathogenesis of IBD. J Gastroenterol. 45:9–16. 2010. View Article : Google Scholar
2	Podolsky DK: Inflammatory bowel disease. N Engl J Med. 347:417–429. 2002. View Article : Google Scholar
3	Ueno F, Matsui T, Matsumoto T, Matsuoka K, Watanabe M and Hibi T; Guidelines Project Group of the Research Group of Intractable Inflammatory Bowel Disease subsidized by the Ministry of Health, Labour and Welfare of Japan and the Guidelines Committee of the Japanese Society of Gastroenterology. Evidence-based clinical practice guidelines for Crohn’s disease, integrated with formal consensus of experts in Japan. J Gastroenterol. 48:31–72. 2013.
4	Imaeda H, Andoh A and Fujiyama Y: Development of a new immunoassay for the accurate determination of anti-infliximab antibodies in inflammatory bowel disease. J Gastroenterol. 47:136–143. 2012. View Article : Google Scholar : PubMed/NCBI
5	Sartor RB: Microbial influences in inflammatory bowel diseases. Gastroenterology. 134:577–594. 2008. View Article : Google Scholar : PubMed/NCBI
6	Mizoguchi A and Mizoguchi E: Inflammatory bowel disease, past, present and future: lessons from animal models. J Gastroenterol. 43:1–17. 2008. View Article : Google Scholar : PubMed/NCBI
7	Sartor RB: Mechanisms of disease: pathogenesis of Crohn’s disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol. 3:390–407. 2006.
8	Hamilton MJ, Snapper SB and Blumberg RS: Update on biologic pathways in inflammatory bowel disease and their therapeutic relevance. J Gastroenterol. 47:1–8. 2012. View Article : Google Scholar : PubMed/NCBI
9	Wirtz S and Neurath MF: Mouse models of inflammatory bowel disease. Adv Drug Deliv Rev. 59:1073–1083. 2007. View Article : Google Scholar : PubMed/NCBI
10	Braun J and Wei B: Body traffic: ecology, genetics, and immunity in inflammatory bowel disease. Annu Rev Pathol. 2:401–429. 2007. View Article : Google Scholar : PubMed/NCBI
11	Seksik P, Sokol H, Lepage P, et al: Review article: the role of bacteria in onset and perpetuation of inflammatory bowel disease. Aliment Pharmacol Ther. 24(Suppl 3): 11–18. 2006. View Article : Google Scholar : PubMed/NCBI
12	Elson CO, Cong Y, McCracken VJ, Dimmitt RA, Lorenz RG and Weaver CT: Experimental models of inflammatory bowel disease reveal innate, adaptive, and regulatory mechanisms of host dialogue with the microbiota. Immunol Rev. 206:260–276. 2005. View Article : Google Scholar : PubMed/NCBI
13	Frank DN, St Amand AL, Feldman RA, Boedeker EC, Harpaz N and Pace NR: Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci USA. 104:13780–13785. 2007. View Article : Google Scholar
14	Andoh A, Kuzuoka H, Tsujikawa T, et al: Multicenter analysis of fecal microbiota profiles in Japanese patients with Crohn’s disease. J Gastroenterol. 47:1298–1307. 2012.PubMed/NCBI
15	Kuwahara E, Asakura K, Nishiwaki Y, et al: Effects of family history on inflammatory bowel disease characteristics in Japanese patients. J Gastroenterol. 47:961–968. 2012. View Article : Google Scholar : PubMed/NCBI
16	Imaeda H, Bamba S, Takahashi K, et al: Relationship between serum infliximab trough levels and endoscopic activities in patients with Crohn’s disease under scheduled maintenance treatment. J Gastroenterol. May 11–2013.(Epub ahead of print).
17	Nagalingam NA and Lynch SV: Role of the microbiota in inflammatory bowel diseases. Inflamm Bowel Dis. 18:968–984. 2012. View Article : Google Scholar : PubMed/NCBI
18	Andoh A, Imaeda H, Aomatsu T, et al: Comparison of the fecal microbiota profiles between ulcerative colitis and Crohn’s disease using terminal restriction fragment length polymorphism analysis. J Gastroenterol. 46:479–486. 2011.
19	Atarashi K, Tanoue T, Shima T, et al: Induction of colonic regulatory T cells by indigenous Clostridium species. Science. 331:337–341. 2011. View Article : Google Scholar : PubMed/NCBI
20	Sokol H, Pigneur B, Watterlot L, et al: Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci USA. 105:16731–16736. 2008. View Article : Google Scholar
21	Sokol H, Seksik P, Furet JP, et al: Low counts of Faecalibacterium prausnitzii in colitis microbiota. Inflamm Bowel Dis. 15:1183–1189. 2009.
22	Fujimoto T, Imaeda H, Takahashi K, et al: Decreased abundance of Faecalibacterium prausnitzii in the gut microbiota of Crohn’s disease. J Gastroenterol Hepatol. 28:613–619. 2013.
23	Best WR, Becktel JM, Singleton JW and Kern F Jr: Development of a Crohn’s disease activity index. National Cooperative Crohn’s Disease Study. Gastroenterology. 70:439–444. 1976.
24	Hayashi H, Sakamoto M, Kitahara M and Benno Y: Diversity of the Clostridium coccoides group in human fecal microbiota as determined by 16S rRNA gene library. FEMS Microbiol Lett. 257:202–207. 2006.
25	Matsumoto M, Sakamoto M, Hayashi H and Benno Y: Novel phylogenetic assignment database for terminal-restriction fragment length polymorphism analysis of human colonic microbiota. J Microbiol Methods. 61:305–319. 2005. View Article : Google Scholar
26	Sakamoto M, Takeuchi Y, Umeda M, Ishikawa I and Benno Y: Application of terminal RFLP analysis to characterize oral bacterial flora in saliva of healthy subjects and patients with periodontitis. J Med Microbiol. 52:79–89. 2003. View Article : Google Scholar : PubMed/NCBI
27	Marsh TL, Saxman P, Cole J and Tiedje J: Terminal restriction fragment length polymorphism analysis program, a web-based research tool for microbial community analysis. Appl Environ Microbiol. 66:3616–3620. 2000. View Article : Google Scholar : PubMed/NCBI
28	Blair YI, McMahon AD and Macpherson LM: Comparison and relative utility of inequality measurements: as applied to Scotland’s child dental health. PLoS One. 8:e585932013.PubMed/NCBI